Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Spermidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.93 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.93 |
| ▸ | CA6 | P23280 | 5/20 | 0.93 |
| ▸ | CA7 | P43166 | 5/20 | 0.93 |
| ▸ | CA9 | Q16790 | 5/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.93 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.93 |
| ▸ | CA4 | P22748 | 4/20 | 0.93 |
| ▸ | CA5A | P35218 | 4/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.93 |
| ▸ | CA3 | P07451 | 3/20 | 0.93 |
| ▸ | F13A1 | P00488 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | THPO | P40225 | 2/20 | 0.93 |
| ▸ | CA1 | P00915 | 2/20 | 0.93 |
| ▸ | UBE2N | P61088 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermidine SCHEMBL573651 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL3623585 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL573341 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL343877 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL29150448 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL9392489 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL31268131 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL2514294 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL8186500 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL30866180 | 0.97 | LMNA (0.93) | LMNASMN1; SMN2CA12CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116687959-B | Chondroitin sulfate biological polyamine complex, and preparation method and application thereof | 朱小丰 | 2024-10-22 | — | — | CN | disclosed |
| CN-116687959-A | Chondroitin sulfate biological polyamine complex, and preparation method and application thereof | 朱小丰 | 2023-09-05 | — | — | CN | disclosed |
| US-6235468-B1 | CLASSIFYING TEST SAMPLE OF GENOMIC NUCLEOTIDE SEQUENCES; INCUBATE TEST SAMPLE WITH PRIMER, EXPAND PRIMER, DETERMINE GENETIC VARATION IN SEQUENCES OF THE AMPLIFICATION PRODUCTS | ZENECA LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0530009-B1 | Method of characterising genomic DNA | ZENECA LTD (GB) | 1999-01-13 | — | — | EP | disclosed |
| US-5853989-A | Method of characterisation of genomic DNA | ZENECA LIMITED (GB) | 1998-12-29 | — | — | US | disclosed |
| US-5811235-A | AMPLIFICATION OF TANDEMLY REPEATED REGION OF GENOMIC DNA, SEPARATION OF SET OF AMPLIFICATION PRODUCTS TO PROVIDE SAMPLE CODE | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| US-5773257-A | GENETIC ENGINEERING | STRATAGENE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5646019-A | Method for producing primed nucleic acid templates | STRATAGENE (US) | 1997-07-08 | — | — | US | disclosed |
| US-5605824-A | THERMOSTABLE DNA POLYMERASE, POLYNUCLEOTIDE AMPLIFICATION PRIMER, TARGETS, MAGNESIUM COMPOUNDS AS ACTIVATOR, BUFFER AND NONIONIC DETERGENTS | STRATAGENE (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0731177-A2 | Method of characterising genomic DNA | ZENECA LIMITED (GB) | 1996-09-11 | — | — | EP | disclosed |
| EP-0530009-A2 | Method of characterising genomic DNA | ZENECA LIMITED (GB) | 1993-03-03 | — | — | EP | disclosed |
| EP-0186271-B1 | METHOD OF CHARACTERISING A TEST SAMPLE OF GENOMIC DNA | THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital (GB) | 1991-12-18 | — | — | EP | disclosed |
| WO-1991006679-A1 | AN IMPROVED METHOD FOR HYBRIDIZING NUCLEIC ACIDS USING SINGLE-STRANDED NUCLEIC ACID BINDING PROTEIN | STRATAGENE (US) | 1991-05-16 | — | — | WO | disclosed |
| EP-0370719-A2 | Extended nucleotide sequences | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-30 | — | — | EP | disclosed |
| EP-0342717-A2 | Polynucleotide probes | THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital (GB) | 1989-11-23 | — | — | EP | disclosed |
| US-4843006-A | GENETIC VECTORS | MONSANTO COMPANY (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0108045-B1 | RECA PROMOTER DEPENDENT POLYPEPTIDE PRODUCTION | Monsanto Company (US) | 1988-12-07 | — | — | EP | disclosed |
| EP-0186271-A1 | Method of characterising a test sample of genomic DNA | THE LISTER INSTITUTE OF PREVENTIVE MEDICINE Royal National Orthopaedic Hospital (GB) | 1986-07-02 | — | — | EP | disclosed |
| WO-1986002948-A1 | POLYNUCLEOTIDE PROBES | LISTER INSTITUTE OF PREVENTIVE MEDICINE (GB) | 1986-05-22 | — | — | WO | disclosed |
| EP-0108045-A1 | RecA promoter dependent polypeptide production | Monsanto Company (US) | 1984-05-09 | — | — | EP | disclosed |